Current Opinion in Pulmonary Medicine
Are you a researcher?
Create a profile to get free access to personal recommendations for colleagues and new articles.
SCImago
Q2
WOS
Q2
Impact factor
2.8
SJR
0.949
CiteScore
6.2
Categories
Pulmonary and Respiratory Medicine
Areas
Medicine
Years of issue
1995-2025
journal names
Current Opinion in Pulmonary Medicine
CURR OPIN PULM MED
Top-3 citing journals

Current Opinion in Pulmonary Medicine
(909 citations)

Chest
(642 citations)

PLoS ONE
(593 citations)
Top-3 organizations

University of Southern California
(64 publications)

Imperial College London
(42 publications)

Harvard University
(31 publications)

Imperial College London
(13 publications)

Cleveland Clinic
(10 publications)

Maastricht University
(10 publications)
Top-3 countries
Most cited in 5 years
Found
Publications found: 4075
Q2

Improvement of torularhodin production by Rhodotorula glutinis through the stimulation of physicochemical stress and application of the bioproduct as an additive in the food industry
de Lima J.G., Veríssimo N.V., de Azevedo Lima C., Picheli F.P., de Paula A.V., Santos-Ebinuma V.D.
Q2
Bioprocess and Biosystems Engineering
,
2025
,
citations by CoLab: 0

Q2

Constructing pyrG marker by CRISPR/Cas facilities the highly-efficient precise genome editing on industrial Aspergillus niger strain
Sun J., Jiang X., Xu F., Tian X., Chu J.
To prevent the unique difficulty of hygromycin-based gene editing on industrial A. niger strain and increase the working efficiency, the local pyrG marker was removed by well-designed dual sgRNAs and repair template through Cas9-ribonucleoprotein (RNP) strategy in this study. The positive rate of the desired pyrG auxotroph construction was 100%, while no transformant was observed using the traditional methods. The complementation strain showed similar fermentation character as the starting strain. Moreover, an efficient and seamless knock out plasmid-based strategy was established, achieving positive rate at 90% and 50% for challenging Δku70 and Δku80 respectively. Further, combined hygromycin markers and miniaturization cultivation were conducted to select the poor growth strain. Finally, skillfully designed sgRNA and amdS counter-selection repair template were used to obtain ERG3Tyr185 mutation. A highly-efficient precise strategy was established for A. niger through a diagnostic PCR method, with nearly 100% positive rate. Highly- precise desired point mutation was achieved by the developed gene toolbox.
Q2

Nutrient removal performance and microbial composition analysis in hybrid membrane bioreactor for municipal wastewater treatment
Tari K., Samarghandi M.R., Shokoohi R., Asgari G., Poorasgari E., Pezhman Karami, Afshar S.
The removal of nutrients from wastewater to reduce the toxicity of these compounds to the environment requires more space in wastewater treatment plants to establish anaerobic, anoxic and aerobic treatment stages. To address this limitation, researchers have developed practical, intensive hybrid treatment systems that enhance nutrient removal performance while requiring less space. However, the implementation of hybrid systems within a reactor introduces the interaction between the attached and suspended growth that can influence the microbial community structure and the performance of the system, so it is crucial to understand the composition of the microbial communities involved in hybrid growth to optimize control strategies in these systems. This study investigated the microbial community structure of the integrated moving bed membrane bioreactor (IMBMBR) system and its impact on nutrient removal in municipal wastewater. The findings demonstrated that the effluent quality was improved with the IMBMBR. The efficiency of removing COD, BOD5, $${\text{NH}}_{4}^{+}\text{-N}$$ and $${\text{PO}}_{4}^{3-}\text{-P}$$ in the IMBMBR were 91 ± 4.0%, 95 ± 4.0%, 99 ± 0.2% and 24 ± 3.0%, respectively. The IMBMBR had better nitrite oxidation and complete nitrification by increasing the diversity and abundance of effective bacteria. The abundance of Proteobacteria, Bacteroidetes and Nitrospira was enhanced in IMBMBR. Coexistence of ammonia-oxidizing bacteria (AOB) and nitrite-oxidizing bacteria (NOB) in IMBMBR led to increased nutrient removal. The study results suggest that IMBMBR can be an effective process for nutrient removal, achieving quality standards that comply with legal requirements for wastewater in municipal and industries with limited space for establishing treatment facilities. Additionally, this process can be quickly implemented as an upgrade to existing wastewater treatment plants, avoiding the need to develop an entirely new system.
Q2

Bioinspired synthesis of copper oxide nanoparticles using aqueous extracts of Cladophora glomerata (L.) Kuetz and their potential biomedical applications
Kumar V., Singh Y., Kaushal S., Kumar R.
Present study deals with the green fabrication of copper oxide nanoparticles (CuO NPs) employing cell-free aqueous extract of Cladophora glomerata (L.) Kuetz, freshwater algal species. The UV–visible, FTIR, XRD, FESEM, HRTEM, EDX, BET, XPS and Raman spectroscopic techniques were used to confirm and characterize the biosynthesized CuO NPs. The UV–Vis analysis revealed a sharp peak at 264 nm with a band gap of 3.7 eV, which was attributable to the fabrication of CuO NPs. FESEM and HRTEM detect the spherical-shaped morphology with size between 40 and 50 nm. The biochemical profiling of cell free extract of the C. glomerata by Gas chromatography–mass spectrometry (GC–MS) revealed the presence of various bioactive biomolecules that may acts as a precursor for the fabrication of CuO NPs. The antibacterial study of fabricated CuO NPs revealed significant growth inhibitory potential against selected bacterial strains Klebsiella pneumoniae and Bacillus cereus with an IC50 value of 10 μg/ml. The synthesized CuO NPs also displayed strong DPPH radical scavenging (IC50 value 11.25 mg/L) and total antioxidant (IC50 value 11 mg/L) properties. Further, the anticancer activity of fabricated CuO NPs was studied employing a human hepatocellular carcinoma (HepG2) cell line by MTT assay, which marks their ability to diminish the 50% cell with IC50 value of 168.6 µg/ml. Overall, the findings confirmed that CuO NPs fabricated employing cell-free extract of C. glomerata have the potential to be used as active agent in various biomedical applications after further detailed clinical investigations.
Q2

Antimicrobial, antibiofilm, and antiurease activities of green-synthesized Zn, Se, and ZnSe nanoparticles against Streptococcus salivarius and Proteus mirabilis
Gurkok S., Ozdal M., Cakici T., Kurbanoglu E.B.
Abstract
This study assesses the antimicrobial, antibiofilm, and antiurease properties of selenium (Se), zinc (Zn), and zinc selenide (ZnSe) nanoparticles (NPs) against clinically pathogenic strains of Streptococcus salivarius and Proteus mirabilis. The Se, Zn, and ZnSe NPs, synthesized by Pseudomonas aeruginosa OG1, were characterized using transmission electron microscopy (TEM) revealing average sizes of approximately 30 ± 10 nm, 30 ± 15 nm, and 40 ± 10 nm, respectively. Atomic force microscopy (AFM) was used to examine the morphological and topological characteristics of the NPs. The structural and crystal characteristics were investigated using X-ray diffraction (XRD). Among the evaluated NPs, Zn NPs at a concentration of 200 mg/mL exhibited the most substantial growth inhibition zone against S. salivarius. Conversely, the highest antibiofilm activity was observed against P. mirabilis, notably with 200 µg/mL Zn NPs. In the context of antiurease activity, both 100 μg Zn and ZnSe NPs caused complete urease inhibition (100%) in P. mirabilis within the initial 5 h, with notable inhibition rates of 94% and 80%, respectively, observed against S. salivarius. Significantly, in the current landscape of NP research primarily focused on antimicrobial and antibiofilm properties, our study stands out due to its pioneering exploration of antiurease activities with these NPs. This distinctive emphasis on antiurease effects contributes original and unique value to our study, offering novel insights into the broader spectrum of NP applications, and paving the way for potential therapeutic advancements.
Q2

Nanofiltration-based purification process for whole-cell transformed prebiotic galactooligosaccharides
Srivastava A., Rastogi A., Jaswal A.S., Sahu J.K., Agarwal G.P., Mishra S.
The enrichment of galactooligosaccharides (GOS), synthesized by whole cells of Kluyveromyces marxianus 3551 in a 5.0-L bioreactor, was investigated in this study. The synthesized sugar mixture containing 17.89% (w/w of total carbohydrates) of GOS with 15.57% (w/w of total carbohydrates) of lactose, and 66.54% (w/w of total carbohydrates) monosaccharides as impurities, was subjected to nanofiltration for enrichment of GOS. Three distinct spiral wound membranes, namely, NFPS-01(polysulfone), NFCA-02 (cellulose acetate), and NFPES-03 (polyethersulfone) were tested out of which the NFPES-03 performed the best for fractionation of the GOS mixture. The polyethersulphone membrane (cut-off 400–1000 Da) was evaluated at 30 ℃ and 50 ℃, at different transmembrane pressures or TMP (15, 20, 25 bar) and a combination of high temperature (50 ℃) and low pressure (15 bar) gave the greatest difference in the trisaccharide and disaccharide/monosaccharide rejection percentages, resulting in enrichment of GOS. An analysis of the sugar concentrations in the retentate samples by high-performance liquid chromatography indicated the percentage recovery of GOS in the integrated process to be 88.8%. Measurement of the growth profile of several microbes on the nano-filtered GOS demonstrated its effectiveness as a prebiotic source.
Q2

Recycling the recyclers: strategies for the immobilisation of a PET-degrading cutinase
Fritzsche S., Popp M., Spälter L., Bonakdar N., Vogel N., Castiglione K.
Abstract
Enzymatic degradation of polyethylene terephthalate (PET) represents a sustainable approach to reducing plastic waste and protecting fossil resources. The cost efficiency of enzymatic PET degradation processes could be substantially improved by reusing the enzymes. However, conventional immobilisation strategies, such as binding to porous carriers, are challenging as the immobilised enzyme can only interact with the macromolecular solid PET substrate to a limited extent, thus reducing the degradation efficiency. To mitigate this challenge, this work compared different immobilisation strategies of the PET-degrading cutinase ICCGDAQI. Immobilisation approaches included enzyme fixation via linkers to carriers, the synthesis of cross-linked enzyme aggregates with different porosities, and immobilisation on stimulus-responsive polymers. The highest degradation efficiencies were obtained with the pH-responsive material Kollicoat®, where 80% of the initial enzyme activity could be recovered after immobilisation. Degradation of textile PET fibres by the cutinase-Kollicoat® immobilisate was investigated in batch reactions on a 1 L-scale. In three consecutive reaction cycles, the product yield of the released terephthalic acid exceeded 97% in less than 14 h. Even in the fifth cycle, 78% of the maximum yield was achieved in the same reaction time. An advantage of this process is the efficient pH-dependent recovery of the immobilisate after the reaction, which integrates seamlessly into the terephthalic acid recovery by lowering the pH after hydrolysis. This integration therefore not only simplifies the downstream processing, but also provides a cost-effective and resource-efficient solution for both enzyme reuse and product separation after PET degradation, making it a promising approach for industrial application.
Q2

Microbial community structure and functional characteristics in a membrane bioreactor used for real rural wastewater treatment
Wang Y., Su S., Qiu H., Guo L., Zhao W., Qin Y., Wang C., Zhao Z., Ding X., Liu G., Hu T., Wang Z.
Membrane bioreactors (MBRs) have been widely used in the field of wastewater treatment because of their small footprint and high treatment efficiency. In this research, 10 rural wastewater treatment sites in China that employ the MBR process were systematically studied. Specifically, treatment of actual domestic wastewater using MBRs was examined by high-throughput 16S rRNA gene sequencing to explore the microbial community composition and perform function prediction. The data of water quality parameters revealed high removal rates of chemical oxygen demand and NH4+–N in all the sites. Proteobacteria were absolutely dominant in all the sites. Thauera, Nitrospira, Ferribacterium, and Dechloromonas were the main functional genera responsible for nitrogen and phosphorus removal at the tested sites. Nitrospira includes conventional nitrite-oxidizing bacteria and complete ammonia-oxidizing bacteria. Among them, 26 genes related to nitrogen metabolism were retrieved according to gene prediction, which verified the good NH4+–N removal efficiency at the tested sites. This study focuses on the analysis of microbial community structure and functional characteristics of MBR-based treatment systems for rural wastewater treatment, thereby providing a microbial basis for improving rural wastewater treatment processes.
Q2

Metabolic engineering of Escherichia coli for enhanced production of p-coumaric acid via L-phenylalanine biosynthesis pathway
Jeong C., Han S.H., Lim C.G., Kim S.C., Jeong K.J.
p-Coumaric acid (p-CA), an invaluable phytochemical, has novel bioactivities, including antiproliferative, anxiolytic, and neuroprotective effects, and is the main precursor of various flavonoids, such as caffeic acid, naringenin, and resveratrol. Herein, we report the engineering of Escherichia coli for de novo production of p-CA via the PAL-C4H pathway. As the base strain, we used the E. coli H-02 strain, which was previously engineered for sufficient supplementation of L-phenylalanine, the main precursor of p-CA. For the bioconversion of L-Phe to p-CA, we constructed and optimized an expression system for phenylalanine ammonia lyase (SmPAL), codon-optimized cinnamate 4-hydroxylase (AtC4H), and its redox partner, cytochrome P450 reductase (AtCPR1). We confirmed that the engineered cell showed higher production of p-CA at 30 °C and the addition of 0.5 mM 5-aminolevulinic acid could increase the production titer further. Subsequently, the main pathways of acetic acid (poxB and pta-ackA) were eliminated to reduce its accumulation and restore cell growth. Next, to increase the available pool of cofactor (NADPH), the co-expression system of the zwf gene in the pentose phosphate pathway (PPP) was integrated into genome and the expression level was optimized with synthetic promoters. Finally, by optimizing fed-batch culture in a 5 L-scale bioreactor, the engineered strain achieved 1.5 g/L p-CA with a productivity of 31.8 mg/L/h.
Q2

Bioprocess development for microbial production and purification of cellobiose lipids by the smut fungus Ustilago maydis DSM 4500
Valkenburg A.D., Teke G.M., van Rensburg E., Pott R.W.
AbstractCellobiose lipids (CBLs) are a class of glycolipid biosurfactants produced by various fungal strains. These compounds have gained significant interest due to their surface-active and antifungal properties, which are comparable to traditional synthetic surfactants and antimicrobials. Despite their potential applicability in various cosmetic, pharmaceutical, and agricultural formulations, significantly less research has been focused on their production and purification in comparison to other glycolipid biosurfactants, such as mannosylerythritol lipids (MELs) and sophorolipids. Hence, this work proposes the development of a bioprocess that involves the microbial production and high-level chromatographic purification of CBLs from a submerged culture of Ustilago maydis DSM 4500. After a highly purified CBL product was obtained, the factors affecting the production of this glycolipid were investigated. It was demonstrated that U. maydis DSM 4500 produces a specific structural variant of CBLs at a concentration of 1.36 g/L on an optimized the growth medium. Also, it was established that when the C/N ratio was decreased, the CBL titer increased by 2.3-fold. Furthermore, supplementing the culture with ZnSO4 at a concentration of 0.04 mg/L further increased CBL concentration to 4.95 g/L, representing the highest CBL titer achieved in a single-stage bioprocess to date. This study developed a methodology for utilizing U. maydis as a high-level CBL producer, which could challenge other familiar CBL producers, such as Sporisorium scitamineum and Cryptococcus humicola.
Q2

Enhancement of FK520 production in Streptomyces hygroscopicus var. ascomyceticus ATCC 14891 by overexpressing the regulatory gene fkbR2
Xiao X., Fu Y., Zhang D., Gao S.
Ascomycin (FK520) is a 23-membered macrolide antibiotic primarily produced by the Streptomyces hygroscopicus var. ascomyceticus. Structurally similar to tacrolimus and rapamycin, it serves as an effective immunosuppressant widely used in the treatment of rejection reactions after organ transplantation and certain autoimmune diseases. Currently, FK520 is mainly produced through microbial fermentation, but its yield remains low. Since the gene fkbR2 is a regulatory gene within the FK520 biosynthesis gene cluster that has not been studied, this paper focuses on the overexpression of the gene fkbR2 in Streptomyces hygroscopicus var. ascomyceticus ATCC 14891 (WT). By constructing a strain with overexpressed fkbR2 gene, we initially obtained a high-yield strain R2-17 through shake flask fermentation, with a 28% increase in yield compared to WT. In the process of further improving the stability of the high-yield strain, this paper defines two indices: high-yield index and stability index. After two consecutive rounds of natural breeding, strain R2-17 achieved a high-yield index of 100% and a stability index of 80%. Finally, the high-yield strain R2-17–3-10 was successfully screened, and the yield was increased by 34% compared with the strain WT, reaching 686.47 mg/L. A comparative analysis between the high-yield strain R2-17–3-10 and the original strain WT revealed differences in fermentation process parameters such as FK520 synthesis rate, pH, bacterial growth, glycerol consumption rate, ammonia nitrogen level, and ammonium ion concentration. In addition, the transcription levels of genes involved in the synthesis of precursors 4,5-dihydroxycyclohex-1-enecarboxylic acid (fkbO), ethylmalonyl-CoA (fkbE, fkbU, fkbS), and pipecolic acid (fkbL), as well as pathway-specific regulatory genes (fkbN, fkbR1), were significantly increased at different time points in the high-yield strain R2-17–3-10. EMSAs analysis showed that the FkbR2 protein could not bind to the promoter region of above genes. This suggests that the gene fkbR2 may enhance the supply of FK520 synthetic precursors by indirectly regulating the transcription levels of these genes, thereby promoting an increase in FK520 production. These results demonstrate that modifying genes within the biosynthetic gene clusters of natural products can be successfully applied to increase the yields of industrially and clinically important compounds. However, it is found that fkbR2 gene is a regulatory gene that has not been fully studied, and it is worth further studying its regulatory mechanism.
Q2

Environmental bioremediation of pharmaceutical residues: microbial processes and technological innovations: a review
Jayasekara U.G., Hadibarata T., Hindarti D., Kurniawan B., Jusoh M.N., Gani P., Tan I.S., Yuniarto A., Rubiyatno, Khamidun M.H.
The ubiquitous presence of pharmaceuticals and personal care products (PPCPs) in the environment has become a significant concern due to their persistence, bioaccumulation potential in biota, and diverse implications for human health and wildlife. This review provides an overview of the current state-of-the-art in environmental bioremediation techniques for reducing pharmaceutical residues, with a special emphasis on microbial physiological aspects. Numerous microorganisms, including algae, bacteria or fungi, can biodegrade various pharmaceutical compounds such as antibiotics, analgesics and beta-blockers. Some microorganisms are capable of transferring electrons within the cell, and this feature can be harnessed using Bio Electrochemical Systems (BES) to potentiate the degradation of pharmaceuticals present in wastewater. Moreover, researchers are evaluating the genetic modification of microbial strains to improve their degradation capacity and expand list of target compounds. This includes also discuss how environment changes, such as fluctuations in temperature or pH, may affect bioremediation efficiency. Furthermore, the presence of pharmaceuticals in the environment is emphasised as a major public health issue because it increases the chance for antibiotic-resistant bacteria emerging. This review combines existing information and outlines needed research areas for improving bioremediation technologies in the future.
Q2

Harnessing the power of microbial fuel cells as pioneering green technology: advancing sustainable energy and wastewater treatment through innovative nanotechnology
Ali H.E., Hemdan B.A., El-Naggar M.E., El-Liethy M.A., Jadhav D.A., El-Hendawy H.H., Ali M., El-Taweel G.E.
Abstract
The purpose of this review is to gain attention about intro the advanced and green technology that has dual action for both clean wastewater and produce energy. Water scarcity and the continuous energy crisis have arisen as major worldwide concerns, requiring the creation of ecologically friendly and sustainable energy alternatives. The rapid exhaustion of fossil resources needs the development of alternative energy sources that reduce carbon emissions while maintaining ecological balance. Microbial fuel cells (MFCs) provide a viable option by producing power from the oxidation of organic and biodegradable chemicals using microorganisms as natural catalysts. This technology has sparked widespread attention due to its combined potential to cleanse wastewater and recover energy. The review presents a complete examination of current advances in MFCs technology, with a focus on the crucial role of anode materials in improving their performance. Moreover, different anode materials and their nanoscale modifications are being studied to boost MFC efficiency. This current review also focused on the effects of surface modifications and different anode compositions on power generation and system stability. It also investigates the electrochemical principles behind these enhancements, providing insights into the economic potential of MFCs. MFCs provide a long-term solution to energy and environmental issues by addressing both wastewater treatment and energy production.
Q2

Computational fluid particle dynamics modeling of tangential flow filtration in perfusion cell culture
Hayati H., Kurtz C., Feng Y., Khattak S.
Membrane fouling is a common and complex challenge with cell culture perfusion process in biopharmaceutical manufacturing that can have detrimental effects on the process performance. In this study, we evaluated a method to calculate the hollow fiber membrane resistance at different time points for water and supernatant. In addition, the number of subvisible particles of < 200 nm. diameter suspended in the supernatant were quantified using a nano-flow cytometry method. A computational fluid dynamics (CFD) model was developed to evaluate the impact of feed flow rate and particle count on the transmembrane pressure (TMP). Then a steady-state discrete phase model was applied to incorporate particles into the model and simulate the particles deposition over the membrane wall. The results showed an increase in the number of particles and the membrane resistance along the time course of the perfusion process. The CFD model illustrated that more particle deposition was observed at lower feed stream flow rates. The fraction of deposited particle was reduced by > 50% when the feed flow rate was increased from 35 ml/min to 300 ml/min. Our findings suggest that the total number of subvisible particles has a significant impact on TMP and membrane resistance and, thus, could play a major role in the mechanism of membrane fouling. CFD modeling can be a useful tool to predict the behavior of a process in a specific membrane. CFD simulations could also be used to optimize process parameters to improve membrane cleanability, reduce particle deposition, and reduce the risk of membrane fouling.
Q2

Green synthesized ZnO and ZnO-based composites for wound healing applications
Wafi A., Khan M.M.
In recent years, zinc oxide nanoparticles (ZnO NPs) have gained much attention in biomedical applications because of their distinctive physicochemical features such as low toxicity and biocompatible properties. Traditional methods to produce ZnO NPs sometimes include harmful substances and considerable energy consumption, causing environmental issues and potential health risks. Nowadays, the concern of ZnO production has moved toward environmentally friendly and sustainable synthesis methods, using natural extracts or plant-based precursors. This review discusses the green synthesis of ZnO NPs utilizing various plant extracts for wound healing applications. Moreover, ZnO NPs have antibacterial characteristics, which can prevent infection, a substantial obstacle in wound healing. Their ability to maintain inflammation, proliferation, oxidative stress, and promote angiogenesis proves their critical role in wound closure. In addition, ZnO NPs can also be easily and ideally incorporated with wound dressings and scaffolds such as hydrogel, chitosan, cellulose, alginate, and other materials, due to their exceptional mechanical properties. The latest publication of green synthesis of ZnO NPs and their applications for wound healing has been discussed. Therefore, this review provides a current update of knowledge on the sustainable and biocompatible ZnO NPs for specific applications, i.e., wound healing applications. In addition, the green synthesis of ZnO NPs using plant extracts also provides a particular approach in terms of material preparation, which is different from previous review articles.
Top-100
Citing journals
100
200
300
400
500
600
700
800
900
1000
|
|
Current Opinion in Pulmonary Medicine
909 citations, 1.75%
|
|
Chest
642 citations, 1.24%
|
|
PLoS ONE
593 citations, 1.14%
|
|
Respiratory Medicine
541 citations, 1.04%
|
|
American Journal of Respiratory and Critical Care Medicine
472 citations, 0.91%
|
|
Archivos de Bronconeumologia
355 citations, 0.68%
|
|
Respirology
331 citations, 0.64%
|
|
Clinics in Chest Medicine
320 citations, 0.62%
|
|
Journal of Cystic Fibrosis
315 citations, 0.61%
|
|
Journal of Clinical Medicine
314 citations, 0.6%
|
|
International Journal of Molecular Sciences
311 citations, 0.6%
|
|
Pediatric Pulmonology
302 citations, 0.58%
|
|
Expert Review of Respiratory Medicine
299 citations, 0.58%
|
|
Scientific Reports
297 citations, 0.57%
|
|
Seminars in Respiratory and Critical Care Medicine
292 citations, 0.56%
|
|
BMC Pulmonary Medicine
288 citations, 0.55%
|
|
European Respiratory Journal
275 citations, 0.53%
|
|
Respiratory Research
272 citations, 0.52%
|
|
Journal of Asthma
256 citations, 0.49%
|
|
Frontiers in Immunology
203 citations, 0.39%
|
|
Journal of Allergy and Clinical Immunology
203 citations, 0.39%
|
|
American Journal of Respiratory Cell and Molecular Biology
192 citations, 0.37%
|
|
Respiration
189 citations, 0.36%
|
|
European Respiratory Review
188 citations, 0.36%
|
|
Annals of the American Thoracic Society
188 citations, 0.36%
|
|
Medicine (United States)
186 citations, 0.36%
|
|
Frontiers in Medicine
184 citations, 0.35%
|
|
Sleep Medicine
181 citations, 0.35%
|
|
Sleep and Breathing
173 citations, 0.33%
|
|
Journal of Thoracic Disease
170 citations, 0.33%
|
|
American Journal of Physiology - Lung Cellular and Molecular Physiology
166 citations, 0.32%
|
|
International Journal of Environmental Research and Public Health
153 citations, 0.29%
|
|
Journal of Immunology
152 citations, 0.29%
|
|
Allergy: European Journal of Allergy and Clinical Immunology
145 citations, 0.28%
|
|
Clinical and Experimental Allergy
144 citations, 0.28%
|
|
Revue des Maladies Respiratoires
140 citations, 0.27%
|
|
Lung
138 citations, 0.27%
|
|
Cureus
138 citations, 0.27%
|
|
Thorax
135 citations, 0.26%
|
|
Annals of Allergy, Asthma and Immunology
128 citations, 0.25%
|
|
Clinical Pulmonary Medicine
121 citations, 0.23%
|
|
Frontiers in Pharmacology
119 citations, 0.23%
|
|
Sleep
119 citations, 0.23%
|
|
Paediatric Respiratory Reviews
119 citations, 0.23%
|
|
Current Opinion in Allergy and Clinical Immunology
117 citations, 0.23%
|
|
Diagnostics
114 citations, 0.22%
|
|
Cochrane Database of Systematic Reviews
112 citations, 0.22%
|
|
ERJ Open Research
111 citations, 0.21%
|
|
Journal of Allergy and Clinical Immunology: In Practice
110 citations, 0.21%
|
|
Pulmonary Pharmacology and Therapeutics
102 citations, 0.2%
|
|
BMJ Case Reports
99 citations, 0.19%
|
|
COPD: Journal of Chronic Obstructive Pulmonary Disease
98 citations, 0.19%
|
|
Thrombosis Research
98 citations, 0.19%
|
|
Journal of Clinical Microbiology
96 citations, 0.18%
|
|
Clinical Respiratory Journal
94 citations, 0.18%
|
|
Therapeutic Advances in Respiratory Disease
92 citations, 0.18%
|
|
Internal Medicine
89 citations, 0.17%
|
|
Antimicrobial Agents and Chemotherapy
87 citations, 0.17%
|
|
Jornal Brasileiro de Pneumologia
83 citations, 0.16%
|
|
Biomedicines
83 citations, 0.16%
|
|
BMJ Open
82 citations, 0.16%
|
|
Journal of Bronchology and Interventional Pulmonology
82 citations, 0.16%
|
|
The Lancet Respiratory Medicine
82 citations, 0.16%
|
|
Environmental Health Perspectives
81 citations, 0.16%
|
|
BMC Infectious Diseases
80 citations, 0.15%
|
|
Medicine (Barcelona)
79 citations, 0.15%
|
|
Sleep Medicine Clinics
79 citations, 0.15%
|
|
Respiratory Medicine Case Reports
78 citations, 0.15%
|
|
Journal of Thrombosis and Haemostasis
77 citations, 0.15%
|
|
Annals of Thoracic Surgery
75 citations, 0.14%
|
|
Pneumologie
75 citations, 0.14%
|
|
Experimental and Therapeutic Medicine
75 citations, 0.14%
|
|
Immunology and Allergy Clinics of North America
74 citations, 0.14%
|
|
International Journal of COPD
74 citations, 0.14%
|
|
The Lancet
72 citations, 0.14%
|
|
International Immunopharmacology
70 citations, 0.13%
|
|
Frontiers in Microbiology
69 citations, 0.13%
|
|
Clinical Infectious Diseases
68 citations, 0.13%
|
|
Respiratory Physiology and Neurobiology
67 citations, 0.13%
|
|
Advances in Experimental Medicine and Biology
67 citations, 0.13%
|
|
Journal of Personalized Medicine
66 citations, 0.13%
|
|
Science of the Total Environment
66 citations, 0.13%
|
|
Lung Cancer
66 citations, 0.13%
|
|
Pulmonologiya
65 citations, 0.13%
|
|
Sleep Medicine Reviews
65 citations, 0.13%
|
|
New England Journal of Medicine
64 citations, 0.12%
|
|
Frontiers in Pediatrics
63 citations, 0.12%
|
|
Pediatrics
63 citations, 0.12%
|
|
Journal of Applied Physiology
63 citations, 0.12%
|
|
Expert Opinion on Pharmacotherapy
62 citations, 0.12%
|
|
Tuberculosis and Respiratory Diseases
60 citations, 0.12%
|
|
Thoracic Surgery Clinics
59 citations, 0.11%
|
|
Environmental Research
58 citations, 0.11%
|
|
International Journal of Infectious Diseases
57 citations, 0.11%
|
|
Mayo Clinic Proceedings
57 citations, 0.11%
|
|
Journal of Clinical Sleep Medicine
57 citations, 0.11%
|
|
Breathe
57 citations, 0.11%
|
|
Chronic Respiratory Disease
56 citations, 0.11%
|
|
Pneumologe
56 citations, 0.11%
|
|
Current Allergy and Asthma Reports
55 citations, 0.11%
|
|
Show all (70 more) | |
100
200
300
400
500
600
700
800
900
1000
|
Citing publishers
2000
4000
6000
8000
10000
12000
14000
|
|
Elsevier
13299 citations, 25.6%
|
|
Springer Nature
6488 citations, 12.49%
|
|
Wiley
4262 citations, 8.2%
|
|
Ovid Technologies (Wolters Kluwer Health)
2956 citations, 5.69%
|
|
Taylor & Francis
2671 citations, 5.14%
|
|
MDPI
2094 citations, 4.03%
|
|
Frontiers Media S.A.
1164 citations, 2.24%
|
|
SAGE
1128 citations, 2.17%
|
|
Oxford University Press
883 citations, 1.7%
|
|
American Thoracic Society
873 citations, 1.68%
|
|
Georg Thieme Verlag KG
803 citations, 1.55%
|
|
BMJ
706 citations, 1.36%
|
|
Public Library of Science (PLoS)
666 citations, 1.28%
|
|
European Respiratory Society (ERS)
655 citations, 1.26%
|
|
Hindawi Limited
536 citations, 1.03%
|
|
American Society for Microbiology
447 citations, 0.86%
|
|
AME Publishing Company
423 citations, 0.81%
|
|
S. Karger AG
376 citations, 0.72%
|
|
American Physiological Society
354 citations, 0.68%
|
|
Mary Ann Liebert
247 citations, 0.48%
|
|
Cold Spring Harbor Laboratory
237 citations, 0.46%
|
|
American Chemical Society (ACS)
201 citations, 0.39%
|
|
Cambridge University Press
184 citations, 0.35%
|
|
Spandidos Publications
179 citations, 0.34%
|
|
The American Association of Immunologists
154 citations, 0.3%
|
|
Medknow
138 citations, 0.27%
|
|
American College of Allergy, Asthma, & Immunology
132 citations, 0.25%
|
|
Bentham Science Publishers Ltd.
118 citations, 0.23%
|
|
Institute of Electrical and Electronics Engineers (IEEE)
115 citations, 0.22%
|
|
Jaypee Brothers Medical Publishing
111 citations, 0.21%
|
|
108 citations, 0.21%
|
|
Sociedade Brasileira de Pneumologia e Tisiologia
106 citations, 0.2%
|
|
American Medical Association (AMA)
102 citations, 0.2%
|
|
Japanese Society of Internal Medicine
97 citations, 0.19%
|
|
Walter de Gruyter
96 citations, 0.18%
|
|
Radiological Society of North America (RSNA)
96 citations, 0.18%
|
|
Royal Society of Chemistry (RSC)
94 citations, 0.18%
|
|
American Academy of Pediatrics
91 citations, 0.18%
|
|
IntechOpen
87 citations, 0.17%
|
|
Scientific and Practical Reviewed Journal Pulmonology
84 citations, 0.16%
|
|
Environmental Health Perspectives
83 citations, 0.16%
|
|
JMIR Publications
82 citations, 0.16%
|
|
Baishideng Publishing Group
82 citations, 0.16%
|
|
77 citations, 0.15%
|
|
Microbiology Society
73 citations, 0.14%
|
|
IOP Publishing
72 citations, 0.14%
|
|
Mark Allen Group
71 citations, 0.14%
|
|
Massachusetts Medical Society
70 citations, 0.13%
|
|
American Society for Clinical Investigation
68 citations, 0.13%
|
|
The American Academy of Sleep Medicine
65 citations, 0.13%
|
|
F1000 Research
62 citations, 0.12%
|
|
SciELO
60 citations, 0.12%
|
|
American Society for Biochemistry and Molecular Biology
58 citations, 0.11%
|
|
American Association for Cancer Research (AACR)
58 citations, 0.11%
|
|
Impact Journals
55 citations, 0.11%
|
|
Annual Reviews
54 citations, 0.1%
|
|
American Roentgen Ray Society
49 citations, 0.09%
|
|
The Korean Academy of Tuberculosis and Respiratory Diseases
49 citations, 0.09%
|
|
PAGEPress Publications
47 citations, 0.09%
|
|
Proceedings of the National Academy of Sciences (PNAS)
45 citations, 0.09%
|
|
Media Sphere Publishing House
41 citations, 0.08%
|
|
American Society for Pharmacology and Experimental Therapeutics
39 citations, 0.08%
|
|
Hans Publishers
37 citations, 0.07%
|
|
American Society of Hematology
36 citations, 0.07%
|
|
Research Square Platform LLC
35 citations, 0.07%
|
|
XMLink
35 citations, 0.07%
|
|
Scientific Research Publishing
33 citations, 0.06%
|
|
American Association for the Advancement of Science (AAAS)
32 citations, 0.06%
|
|
Portland Press
31 citations, 0.06%
|
|
Federation of American Societies for Experimental Biology (FASEB)
31 citations, 0.06%
|
|
29 citations, 0.06%
|
|
The Endocrine Society
29 citations, 0.06%
|
|
Remedium, Ltd.
29 citations, 0.06%
|
|
Oceanside Publications, Inc.
28 citations, 0.05%
|
|
Deutscher Arzte-Verlag GmbH
26 citations, 0.05%
|
|
Japan Society of Sarcoidosis and other Granulomatous Disorders
26 citations, 0.05%
|
|
IOS Press
25 citations, 0.05%
|
|
Consilium Medicum
25 citations, 0.05%
|
|
24 citations, 0.05%
|
|
Eco-Vector LLC
23 citations, 0.04%
|
|
Soonchunhyang University
23 citations, 0.04%
|
|
SLACK
22 citations, 0.04%
|
|
American Society of Clinical Oncology (ASCO)
20 citations, 0.04%
|
|
Rockefeller University Press
19 citations, 0.04%
|
|
Akademiai Kiado
19 citations, 0.04%
|
|
AACN Publishing
19 citations, 0.04%
|
|
World Scientific
18 citations, 0.03%
|
|
American Diabetes Association
18 citations, 0.03%
|
|
Centers for Disease Control and Prevention (CDC)
18 citations, 0.03%
|
|
PeerJ
18 citations, 0.03%
|
|
Asian Pacific Organization for Cancer Prevention
18 citations, 0.03%
|
|
Korean Academy of Medical Sciences
18 citations, 0.03%
|
|
Pleiades Publishing
17 citations, 0.03%
|
|
King Faisal Specialist Hospital and Research Centre
17 citations, 0.03%
|
|
Edizioni Minerva Medica
17 citations, 0.03%
|
|
The Korean Academy of Asthma, Allergy and Clinical Immunology and The Korean Academy of Pediatric Al
17 citations, 0.03%
|
|
IGI Global
16 citations, 0.03%
|
|
American Veterinary Medical Association
15 citations, 0.03%
|
|
British Institute of Radiology
15 citations, 0.03%
|
|
The Japanese Circulation Society
15 citations, 0.03%
|
|
Show all (70 more) | |
2000
4000
6000
8000
10000
12000
14000
|
Publishing organizations
10
20
30
40
50
60
70
|
|
University of Southern California
64 publications, 2.49%
|
|
Imperial College London
42 publications, 1.63%
|
|
Harvard University
31 publications, 1.2%
|
|
Baylor College of Medicine
31 publications, 1.2%
|
|
University College London
28 publications, 1.09%
|
|
Johns Hopkins University
28 publications, 1.09%
|
|
McMaster University
26 publications, 1.01%
|
|
Medical College of Wisconsin
25 publications, 0.97%
|
|
Istituti di Ricovero e Cura a Carattere Scientifico
22 publications, 0.86%
|
|
University of Colorado Anschutz Medical Campus
22 publications, 0.86%
|
|
University of Texas MD Anderson Cancer Center
20 publications, 0.78%
|
|
Stanford University
19 publications, 0.74%
|
|
Mayo Clinic
19 publications, 0.74%
|
|
St. Antonius Hospital
19 publications, 0.74%
|
|
University of Padua
18 publications, 0.7%
|
|
University of Toronto
18 publications, 0.7%
|
|
Cleveland Clinic
18 publications, 0.7%
|
|
Maastricht University
17 publications, 0.66%
|
|
University of Washington
17 publications, 0.66%
|
|
Brigham and Women's Hospital
17 publications, 0.66%
|
|
University of Michigan
17 publications, 0.66%
|
|
University of North Carolina at Chapel Hill
17 publications, 0.66%
|
|
University of Colorado Denver
17 publications, 0.66%
|
|
King's College London
16 publications, 0.62%
|
|
Vanderbilt University
16 publications, 0.62%
|
|
University Medical Center Utrecht
16 publications, 0.62%
|
|
University of California, Davis
15 publications, 0.58%
|
|
University of British Columbia
15 publications, 0.58%
|
|
Post graduate Institute of Medical Education and Research
14 publications, 0.54%
|
|
Skåne University Hospital
14 publications, 0.54%
|
|
University College London Hospitals NHS Foundation Trust
14 publications, 0.54%
|
|
Massachusetts General Hospital
14 publications, 0.54%
|
|
University of Alabama at Birmingham
14 publications, 0.54%
|
|
University of Western Australia
13 publications, 0.51%
|
|
University of California, Los Angeles
13 publications, 0.51%
|
|
University of Maryland, Baltimore
13 publications, 0.51%
|
|
University of Calgary
13 publications, 0.51%
|
|
Cornell University
12 publications, 0.47%
|
|
Chinese University of Hong Kong
12 publications, 0.47%
|
|
Northwestern University
12 publications, 0.47%
|
|
Emory University
12 publications, 0.47%
|
|
University of Pennsylvania
12 publications, 0.47%
|
|
Katholieke Universiteit Leuven
11 publications, 0.43%
|
|
University of California, San Francisco
11 publications, 0.43%
|
|
Paris Cité University
11 publications, 0.43%
|
|
University of Amsterdam
11 publications, 0.43%
|
|
University of Cincinnati Medical Center
11 publications, 0.43%
|
|
Maastricht University Medical Center+
10 publications, 0.39%
|
|
Yale University
10 publications, 0.39%
|
|
Boston University
10 publications, 0.39%
|
|
Case Western Reserve University
10 publications, 0.39%
|
|
New York University
10 publications, 0.39%
|
|
Kyoto University
10 publications, 0.39%
|
|
Vanderbilt University Medical Center
10 publications, 0.39%
|
|
Amsterdam University Medical Center
10 publications, 0.39%
|
|
University of Texas Southwestern Medical Center
10 publications, 0.39%
|
|
University of Manitoba
10 publications, 0.39%
|
|
Universitair Ziekenhuis Leuven
9 publications, 0.35%
|
|
University of Cape Town
9 publications, 0.35%
|
|
University of Illinois at Chicago
9 publications, 0.35%
|
|
University Medical Center Groningen
9 publications, 0.35%
|
|
University of Cincinnati
9 publications, 0.35%
|
|
Beth Israel Deaconess Medical Center
9 publications, 0.35%
|
|
Heidelberg University
8 publications, 0.31%
|
|
Sir Charles Gairdner Hospital
8 publications, 0.31%
|
|
Washington University in St. Louis
8 publications, 0.31%
|
|
Ohio State University Wexner Medical Center
8 publications, 0.31%
|
|
University of Chicago
8 publications, 0.31%
|
|
University of Wisconsin–Madison
8 publications, 0.31%
|
|
University of Barcelona
8 publications, 0.31%
|
|
Karolinska Institute
7 publications, 0.27%
|
|
University of Edinburgh
7 publications, 0.27%
|
|
Stellenbosch University
7 publications, 0.27%
|
|
University at Buffalo, State University of New York
7 publications, 0.27%
|
|
Icahn School of Medicine at Mount Sinai
7 publications, 0.27%
|
|
Leiden University Medical Center
7 publications, 0.27%
|
|
Erasmus University Medical Center
7 publications, 0.27%
|
|
University of Kentucky
7 publications, 0.27%
|
|
University of Utah
7 publications, 0.27%
|
|
University of Zurich
6 publications, 0.23%
|
|
University of Oxford
6 publications, 0.23%
|
|
University of Copenhagen
6 publications, 0.23%
|
|
Manchester University NHS Foundation Trust
6 publications, 0.23%
|
|
Drexel University
6 publications, 0.23%
|
|
University of Sydney
6 publications, 0.23%
|
|
Pennsylvania State University
6 publications, 0.23%
|
|
Royal Prince Alfred Hospital
6 publications, 0.23%
|
|
Duke University Hospital
6 publications, 0.23%
|
|
University of Arizona
6 publications, 0.23%
|
|
University of South Florida
6 publications, 0.23%
|
|
McGill University
6 publications, 0.23%
|
|
Tulane University
6 publications, 0.23%
|
|
Sorbonne Paris Nord University
6 publications, 0.23%
|
|
University of Alberta
6 publications, 0.23%
|
|
University of Ottawa
6 publications, 0.23%
|
|
University of Louisville
6 publications, 0.23%
|
|
Seattle Children's Hospital
6 publications, 0.23%
|
|
University College Dublin
6 publications, 0.23%
|
|
Karolinska University Hospital
5 publications, 0.19%
|
|
Sapienza University of Rome
5 publications, 0.19%
|
|
Show all (70 more) | |
10
20
30
40
50
60
70
|
Publishing organizations in 5 years
2
4
6
8
10
12
14
|
|
Imperial College London
13 publications, 2.99%
|
|
Maastricht University
10 publications, 2.3%
|
|
Cleveland Clinic
10 publications, 2.3%
|
|
University of Maryland, Baltimore
8 publications, 1.84%
|
|
University College London
7 publications, 1.61%
|
|
Johns Hopkins University
7 publications, 1.61%
|
|
Harvard University
7 publications, 1.61%
|
|
Vanderbilt University Medical Center
7 publications, 1.61%
|
|
St. Antonius Hospital
7 publications, 1.61%
|
|
University of Colorado Anschutz Medical Campus
7 publications, 1.61%
|
|
University College London Hospitals NHS Foundation Trust
6 publications, 1.38%
|
|
University of Padua
6 publications, 1.38%
|
|
McMaster University
6 publications, 1.38%
|
|
University Medical Center Utrecht
6 publications, 1.38%
|
|
Cornell University
5 publications, 1.15%
|
|
University of Illinois at Chicago
5 publications, 1.15%
|
|
Brigham and Women's Hospital
5 publications, 1.15%
|
|
University of Crete
5 publications, 1.15%
|
|
University of Michigan
5 publications, 1.15%
|
|
Istituti di Ricovero e Cura a Carattere Scientifico
4 publications, 0.92%
|
|
Imperial College Healthcare NHS Trust
4 publications, 0.92%
|
|
University of Edinburgh
4 publications, 0.92%
|
|
Manchester University NHS Foundation Trust
4 publications, 0.92%
|
|
Chinese University of Hong Kong
4 publications, 0.92%
|
|
Baylor College of Medicine
4 publications, 0.92%
|
|
University of British Columbia
4 publications, 0.92%
|
|
Emory University
4 publications, 0.92%
|
|
University of Texas MD Anderson Cancer Center
4 publications, 0.92%
|
|
University of Toronto
4 publications, 0.92%
|
|
University of Cincinnati Medical Center
4 publications, 0.92%
|
|
University of Colorado Denver
4 publications, 0.92%
|
|
Post graduate Institute of Medical Education and Research
3 publications, 0.69%
|
|
Karolinska Institute
3 publications, 0.69%
|
|
University Hospital of Zürich
3 publications, 0.69%
|
|
University of Zurich
3 publications, 0.69%
|
|
Medical University of Graz
3 publications, 0.69%
|
|
Maastricht University Medical Center+
3 publications, 0.69%
|
|
University of Sydney
3 publications, 0.69%
|
|
Monash University
3 publications, 0.69%
|
|
University of Western Australia
3 publications, 0.69%
|
|
Stanford University
3 publications, 0.69%
|
|
Boston University
3 publications, 0.69%
|
|
University of Washington
3 publications, 0.69%
|
|
Massachusetts General Hospital
3 publications, 0.69%
|
|
University of Chicago
3 publications, 0.69%
|
|
Paris Cité University
3 publications, 0.69%
|
|
Icahn School of Medicine at Mount Sinai
3 publications, 0.69%
|
|
University of Texas Southwestern Medical Center
3 publications, 0.69%
|
|
University of Maryland, College Park
3 publications, 0.69%
|
|
Erasmus University Medical Center
3 publications, 0.69%
|
|
University of Pennsylvania
3 publications, 0.69%
|
|
University of Barcelona
3 publications, 0.69%
|
|
University of Calgary
3 publications, 0.69%
|
|
Hospital Clínic de Barcelona
3 publications, 0.69%
|
|
University of Ottawa
3 publications, 0.69%
|
|
University of Exeter
3 publications, 0.69%
|
|
University of Cincinnati
3 publications, 0.69%
|
|
University of Utah
3 publications, 0.69%
|
|
King Saud University
2 publications, 0.46%
|
|
Universitair Ziekenhuis Leuven
2 publications, 0.46%
|
|
Karolinska University Hospital
2 publications, 0.46%
|
|
Skåne University Hospital
2 publications, 0.46%
|
|
Sapienza University of Rome
2 publications, 0.46%
|
|
University Hospital of Bern
2 publications, 0.46%
|
|
Aarhus University Hospital
2 publications, 0.46%
|
|
Oslo University Hospital
2 publications, 0.46%
|
|
Antwerp University Hospital
2 publications, 0.46%
|
|
National University of Singapore
2 publications, 0.46%
|
|
University of Strathclyde
2 publications, 0.46%
|
|
Pennsylvania State University
2 publications, 0.46%
|
|
Charles University
2 publications, 0.46%
|
|
University of Melbourne
2 publications, 0.46%
|
|
Royal Children's Hospital Melbourne
2 publications, 0.46%
|
|
Flinders University
2 publications, 0.46%
|
|
Royal Perth Hospital
2 publications, 0.46%
|
|
University of the Witwatersrand
2 publications, 0.46%
|
|
Stellenbosch University
2 publications, 0.46%
|
|
Washington University in St. Louis
2 publications, 0.46%
|
|
Northwestern University
2 publications, 0.46%
|
|
New York University
2 publications, 0.46%
|
|
University of California, Los Angeles
2 publications, 0.46%
|
|
University of California, San Francisco
2 publications, 0.46%
|
|
University of South Florida
2 publications, 0.46%
|
|
Vanderbilt University
2 publications, 0.46%
|
|
Trinity College Dublin
2 publications, 0.46%
|
|
Witten/Herdecke University
2 publications, 0.46%
|
|
Tulane University
2 publications, 0.46%
|
|
Essen University Hospital
2 publications, 0.46%
|
|
University of Amsterdam
2 publications, 0.46%
|
|
Ludwig Boltzmann Institute for Lung Vascular Research
2 publications, 0.46%
|
|
Medical College of Wisconsin
2 publications, 0.46%
|
|
East Carolina University
2 publications, 0.46%
|
|
Université Bourgogne Franche-Comté
2 publications, 0.46%
|
|
University of Alberta
2 publications, 0.46%
|
|
Louisiana State University
2 publications, 0.46%
|
|
University of Lleida
2 publications, 0.46%
|
|
Seattle Children's Hospital
2 publications, 0.46%
|
|
University College Dublin
2 publications, 0.46%
|
|
University College Cork (National University of Ireland, Cork)
2 publications, 0.46%
|
|
Barts Health NHS Trust
2 publications, 0.46%
|
|
Show all (70 more) | |
2
4
6
8
10
12
14
|
Publishing countries
200
400
600
800
1000
1200
|
|
USA
|
USA, 1002, 38.94%
USA
1002 publications, 38.94%
|
United Kingdom
|
United Kingdom, 238, 9.25%
United Kingdom
238 publications, 9.25%
|
Canada
|
Canada, 140, 5.44%
Canada
140 publications, 5.44%
|
Italy
|
Italy, 110, 4.28%
Italy
110 publications, 4.28%
|
Netherlands
|
Netherlands, 108, 4.2%
Netherlands
108 publications, 4.2%
|
France
|
France, 63, 2.45%
France
63 publications, 2.45%
|
Australia
|
Australia, 60, 2.33%
Australia
60 publications, 2.33%
|
Spain
|
Spain, 60, 2.33%
Spain
60 publications, 2.33%
|
Germany
|
Germany, 47, 1.83%
Germany
47 publications, 1.83%
|
Belgium
|
Belgium, 35, 1.36%
Belgium
35 publications, 1.36%
|
Japan
|
Japan, 30, 1.17%
Japan
30 publications, 1.17%
|
China
|
China, 27, 1.05%
China
27 publications, 1.05%
|
India
|
India, 27, 1.05%
India
27 publications, 1.05%
|
Sweden
|
Sweden, 26, 1.01%
Sweden
26 publications, 1.01%
|
Greece
|
Greece, 24, 0.93%
Greece
24 publications, 0.93%
|
South Africa
|
South Africa, 22, 0.86%
South Africa
22 publications, 0.86%
|
Switzerland
|
Switzerland, 21, 0.82%
Switzerland
21 publications, 0.82%
|
Denmark
|
Denmark, 19, 0.74%
Denmark
19 publications, 0.74%
|
Ireland
|
Ireland, 19, 0.74%
Ireland
19 publications, 0.74%
|
Brazil
|
Brazil, 17, 0.66%
Brazil
17 publications, 0.66%
|
Turkey
|
Turkey, 15, 0.58%
Turkey
15 publications, 0.58%
|
Israel
|
Israel, 13, 0.51%
Israel
13 publications, 0.51%
|
Singapore
|
Singapore, 13, 0.51%
Singapore
13 publications, 0.51%
|
Republic of Korea
|
Republic of Korea, 11, 0.43%
Republic of Korea
11 publications, 0.43%
|
New Zealand
|
New Zealand, 10, 0.39%
New Zealand
10 publications, 0.39%
|
Portugal
|
Portugal, 7, 0.27%
Portugal
7 publications, 0.27%
|
Poland
|
Poland, 7, 0.27%
Poland
7 publications, 0.27%
|
Czech Republic
|
Czech Republic, 7, 0.27%
Czech Republic
7 publications, 0.27%
|
Austria
|
Austria, 6, 0.23%
Austria
6 publications, 0.23%
|
Saudi Arabia
|
Saudi Arabia, 6, 0.23%
Saudi Arabia
6 publications, 0.23%
|
Mexico
|
Mexico, 5, 0.19%
Mexico
5 publications, 0.19%
|
Argentina
|
Argentina, 4, 0.16%
Argentina
4 publications, 0.16%
|
Norway
|
Norway, 4, 0.16%
Norway
4 publications, 0.16%
|
Finland
|
Finland, 4, 0.16%
Finland
4 publications, 0.16%
|
Chile
|
Chile, 4, 0.16%
Chile
4 publications, 0.16%
|
Zambia
|
Zambia, 2, 0.08%
Zambia
2 publications, 0.08%
|
Iraq
|
Iraq, 2, 0.08%
Iraq
2 publications, 0.08%
|
Oman
|
Oman, 2, 0.08%
Oman
2 publications, 0.08%
|
Pakistan
|
Pakistan, 2, 0.08%
Pakistan
2 publications, 0.08%
|
Serbia
|
Serbia, 2, 0.08%
Serbia
2 publications, 0.08%
|
Uruguay
|
Uruguay, 2, 0.08%
Uruguay
2 publications, 0.08%
|
Croatia
|
Croatia, 2, 0.08%
Croatia
2 publications, 0.08%
|
Russia
|
Russia, 1, 0.04%
Russia
1 publication, 0.04%
|
Ukraine
|
Ukraine, 1, 0.04%
Ukraine
1 publication, 0.04%
|
Vietnam
|
Vietnam, 1, 0.04%
Vietnam
1 publication, 0.04%
|
Egypt
|
Egypt, 1, 0.04%
Egypt
1 publication, 0.04%
|
Indonesia
|
Indonesia, 1, 0.04%
Indonesia
1 publication, 0.04%
|
Iceland
|
Iceland, 1, 0.04%
Iceland
1 publication, 0.04%
|
|
, 1, 0.04%
1 publication, 0.04%
|
Malawi
|
Malawi, 1, 0.04%
Malawi
1 publication, 0.04%
|
Mali
|
Mali, 1, 0.04%
Mali
1 publication, 0.04%
|
Peru
|
Peru, 1, 0.04%
Peru
1 publication, 0.04%
|
Slovakia
|
Slovakia, 1, 0.04%
Slovakia
1 publication, 0.04%
|
Thailand
|
Thailand, 1, 0.04%
Thailand
1 publication, 0.04%
|
Tunisia
|
Tunisia, 1, 0.04%
Tunisia
1 publication, 0.04%
|
Montenegro
|
Montenegro, 1, 0.04%
Montenegro
1 publication, 0.04%
|
Ecuador
|
Ecuador, 1, 0.04%
Ecuador
1 publication, 0.04%
|
Yugoslavia
|
Yugoslavia, 1, 0.04%
Yugoslavia
1 publication, 0.04%
|
Show all (28 more) | |
200
400
600
800
1000
1200
|
Publishing countries in 5 years
20
40
60
80
100
120
140
160
180
|
|
USA
|
USA, 161, 37.01%
USA
161 publications, 37.01%
|
United Kingdom
|
United Kingdom, 48, 11.03%
United Kingdom
48 publications, 11.03%
|
Canada
|
Canada, 29, 6.67%
Canada
29 publications, 6.67%
|
Netherlands
|
Netherlands, 26, 5.98%
Netherlands
26 publications, 5.98%
|
Italy
|
Italy, 19, 4.37%
Italy
19 publications, 4.37%
|
France
|
France, 17, 3.91%
France
17 publications, 3.91%
|
Australia
|
Australia, 16, 3.68%
Australia
16 publications, 3.68%
|
Spain
|
Spain, 15, 3.45%
Spain
15 publications, 3.45%
|
Ireland
|
Ireland, 11, 2.53%
Ireland
11 publications, 2.53%
|
Germany
|
Germany, 8, 1.84%
Germany
8 publications, 1.84%
|
Singapore
|
Singapore, 7, 1.61%
Singapore
7 publications, 1.61%
|
China
|
China, 6, 1.38%
China
6 publications, 1.38%
|
Switzerland
|
Switzerland, 6, 1.38%
Switzerland
6 publications, 1.38%
|
Sweden
|
Sweden, 6, 1.38%
Sweden
6 publications, 1.38%
|
Greece
|
Greece, 5, 1.15%
Greece
5 publications, 1.15%
|
South Africa
|
South Africa, 5, 1.15%
South Africa
5 publications, 1.15%
|
Austria
|
Austria, 4, 0.92%
Austria
4 publications, 0.92%
|
Belgium
|
Belgium, 4, 0.92%
Belgium
4 publications, 0.92%
|
Denmark
|
Denmark, 4, 0.92%
Denmark
4 publications, 0.92%
|
India
|
India, 4, 0.92%
India
4 publications, 0.92%
|
Saudi Arabia
|
Saudi Arabia, 4, 0.92%
Saudi Arabia
4 publications, 0.92%
|
Portugal
|
Portugal, 2, 0.46%
Portugal
2 publications, 0.46%
|
Israel
|
Israel, 2, 0.46%
Israel
2 publications, 0.46%
|
Mexico
|
Mexico, 2, 0.46%
Mexico
2 publications, 0.46%
|
Norway
|
Norway, 2, 0.46%
Norway
2 publications, 0.46%
|
Republic of Korea
|
Republic of Korea, 2, 0.46%
Republic of Korea
2 publications, 0.46%
|
Czech Republic
|
Czech Republic, 2, 0.46%
Czech Republic
2 publications, 0.46%
|
Chile
|
Chile, 2, 0.46%
Chile
2 publications, 0.46%
|
Japan
|
Japan, 2, 0.46%
Japan
2 publications, 0.46%
|
Russia
|
Russia, 1, 0.23%
Russia
1 publication, 0.23%
|
Ukraine
|
Ukraine, 1, 0.23%
Ukraine
1 publication, 0.23%
|
Vietnam
|
Vietnam, 1, 0.23%
Vietnam
1 publication, 0.23%
|
Zambia
|
Zambia, 1, 0.23%
Zambia
1 publication, 0.23%
|
|
, 1, 0.23%
1 publication, 0.23%
|
Mali
|
Mali, 1, 0.23%
Mali
1 publication, 0.23%
|
Oman
|
Oman, 1, 0.23%
Oman
1 publication, 0.23%
|
Poland
|
Poland, 1, 0.23%
Poland
1 publication, 0.23%
|
Slovakia
|
Slovakia, 1, 0.23%
Slovakia
1 publication, 0.23%
|
Thailand
|
Thailand, 1, 0.23%
Thailand
1 publication, 0.23%
|
Ecuador
|
Ecuador, 1, 0.23%
Ecuador
1 publication, 0.23%
|
Show all (10 more) | |
20
40
60
80
100
120
140
160
180
|